Pure Gold: Canaccord Suspends Rating After Operational Struggles

On Friday, Pure Gold Mining (TSXV: PGM) announced a number of updates for its investors. First, the company announced that it has received US$6 million from Sprott in a secured first-priority, non-revolving credit facility. In the terms of the facility, PureGold has to provide Sprott with a weekly budget for the business.

PureGold’s CFO, Chris Haubrich stated “The Additional Credit Facility and support from our lending partner Sprott provides the Company with the liquidity and time needed to maintain the positive momentum of the operational turnaround and optimization initiatives currently underway.”

The company also announced an “operational turnaround plan.” This starts off with the company announcing that Mark O’Dea will be taking the role of interim President and Chief Executive Officer, effective immediately. This comes after newcomer Tory Fierro stepped down due to personal health issues.

On top of this, the company has let go roughly 20% of its workforce, with its operation now down to 275 employees. The company also transitioned to a campaign milling schedule, which means the mill is only operational for 2 out of every 4 weeks. The mill will gradually increase use time as mining production increases. On top of this, the development of the Main Ramp has been temporarily paused.

They also announced that the PureGold mine will continue to increase its throughput and will be ramping up towards 800tpd. On top of this, they expect to see an additional $1 million per month in cost-savings.

PureGold currently has 7 analysts covering the stock with an average 12-month price target of $0.95, which represents a 340% upside to the current stock price. Out of the 7 analysts, 1 has a strong buy rating, 2 have buys and 4 have hold ratings on the stock. The street high price target sits at $1.70 or an almost 700% upside.

In Canaccord’s note on the changes, the firm put the company under review, and states this news release left them with more questions than answers. As the company is now under review, Canaccord has suspended its hold rating and C$1 12-month price target on the stock.

Though the note is fairly short, Canaccord says that since PureGold started commercial production in August of 2021, the mine has “significantly underperformed relative to expectations.” While also noting that they have no clear insight into the additional challenges that might come along in the pending updated LOM plan.

Lastly, Canaccord says that they had to put the company under review because of a lack of clarity and “the uncertainty as to how the company will meet its near-term financing requirements.” They will update their rating and price target once there is a more concrete basis from which to value the company.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Silver’s Next Move May Be Built on a Much Stronger Base | Mani Alkhafaji – First Majestic Silver

Guanajuato Silver Q1 Earnings: They Finally Post Positive Net Income

We’re in a New Era of Gold Price Discovery | Ryan King – Equinox Gold

Recommended

Mercado Minerals Drills 1,120 g/t Silver Equivalent Over 1.20 Metres At Copalito

Goliath Resources Targets Expansion, Motherlode Source in 50,000 Metre Surebet Drill Program

Related News

Apple: Canaccord Lowers Price Target On Expected iPhone Demand Drop

As the economy comes to a halt, consumers become more cautious with their wallets. Analysts...

Sunday, January 22, 2023, 01:54:00 PM

BMO Gets Bullish On The Fertilizer Sector

Earlier this month, BMO Capital Markets raised their 12-month price targets on a number of...

Friday, April 15, 2022, 04:38:00 PM

Medmen: Canaccord Raises Price Target, Rating After Q4 Performance

On September 23, Medmen Enterprises (CSE: MMEN) reported their fiscal fourth-quarter financial results. The company...

Saturday, September 25, 2021, 01:05:00 PM

Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target

Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company...

Tuesday, August 18, 2020, 01:46:28 PM

Canaccord Reiterates $6.00 Price Target On Valens Company Following Investor Day

This morning, Canaccord Genuity released their takeaway from hosting their first virtual investor day with...

Friday, November 20, 2020, 02:37:00 PM